vx 765  (MedChemExpress)

Journal: Brain

Article Title: P2X7 receptor-mediated IL-1β release by human brain tissue: the impact of CNS-penetrant potential therapeutics

doi: 10.1093/brain/awag068

Figure Lengend Snippet: Ability of inhibitors of the NLRP3 inflammasome or caspase-1 to inhibit BzATP-induced IL-1β and IL-18 release from LPS-primed hMDM. Human monocyte-derived microglia (hMDM) cultures were preincubated for 1 h in the absence (vehicle) or presence of the NLRP3 inflammasome inhibitor MCC950 ( A and B ) or the caspase-1 inhibitor VX-765 ( C and D ) prior to priming with LPS (100 ng/ml; 2 h), followed by stimulation with BzATP (100 μM) for 4 h. ( A and D ) Three circles to the left ( left y -axis; mean ± SEM) display IL-1β or IL-18 levels in the cell culture supernatants and curve fits (iterative curve fit according to a four-parameter logistic equation) of the impact of the MCC950 or VX-765 upon percentage release relative to the LPS + BzATP response (open circles; 100 µM BzATP). Data are expressed as the mean ± standard error of the mean from five independent donors. Significance was determined using a one-way ANOVA with Dunnett’s post hoc test for comparison of picograms per millilitre BzATP-induced IL-1β or IL-18 release compared with either LPS or vehicle control ( left y -axis), or for comparison of the percentage IL-1β or IL-18 release at each concentration of inhibitor to their relative vehicle control (set to 100%; right y -axis). Significant difference between indicated data: *** P < 0.001. Significant difference from LPS + BzATP: ++ P < 0.01 and +++ P < 0.001. BzATP = 2′(3′)- O -(4-benzoylbenzoyl) ATP; IL = interleukin; LPS = lipopolysaccharide.

Article Snippet: For experiments investigating inflammasome pathway modulation, hMDM were preincubated with the selective inflammasome inhibitor MCC950 (Selleck Chemicals) or the selective caspase-1 inhibitor VX-765 (InvivoGen) or relevant vehicle (water/DMSO; 0.03%) for 1 h prior to priming with LPS (100 ng/ml), for 2 h, followed by stimulation with BzATP for 4 h.

Techniques: Derivative Assay, Cell Culture, Comparison, Control, Concentration Assay

Journal: Science Advances

Article Title: Chemo-metallo nanodrivers for spatiotemporally controlled in situ vaccination

doi: 10.1126/sciadv.aee4577

Figure Lengend Snippet: ( A ) Volcano plot of differentially expressed genes (DEGs) in MFC cells (Control versus DDP + Zn 2+ ). ( B ) KEGG pathway enrichment of DEGs. ( C ) Quantification of extracellular dsDNA. ( D ) JC-1 staining assessed by fluorescence microscopy and flow cytometry. ( E ) γ-H2AX immunofluorescence staining. Scale bar, 20 μm. ( F ) ASC speck colocalization with AIM2, Caspase-1, Caspase-8, and RIPK1. Scale bars, 5 μm (overview) and 1 μm (enlarged). ( G ) Western blot analysis of necroptosis markers (RIPK1, p-RIPK1, MLKL, and p-MLKL) and PANoptosis-related proteins (AIM2 and ZBP1). ( H ) Western blot analysis of apoptosis executors (Caspase-8, Caspase-3, and cleaved forms). ( I ) Western blot analysis of pyroptosis markers (Caspase-1, GSDMD, and cleaved forms). ( J ) Cell viability after DDP + Zn 2+ combined with VX-765, Ac-DEVD-CHO, or Nec-1. ( K ) PANoptosis-related proteins in si AIM2 cells. ( L and M ) cGAS activity (L) and expression (M) under Zn 2+ treatment. ( N ) Violin plot of cGAS expression. ( O ) Western blot analysis of STING pathway (STING, p-STING, TBK1, p-TBK1, IRF3, and p-IRF3). ( P ) CIBERSORT analysis of immune cell infiltration. ( Q ) BMDC maturation (CD80 + CD86 + ) after different treatments. ( R ) Schematic of the DDP + Zn 2+ –induced ICD. Data in (C), (J), and (L) are mean ± SD. Statistical analysis for (C), (J), (L), (N), and (P) used a two-tailed unpaired Student’s t test. (R) was created in BioRender. Fei, G. (2026) https://BioRender.com/8ri399r . * P < 0.05.

Article Snippet: The pharmacological inhibitors VX-765, Ac-DEVD-CHO, and Nec-1 were purchased from MedChemExpress (USA).

Techniques: Control, Staining, Fluorescence, Microscopy, Flow Cytometry, Immunofluorescence, Western Blot, Analysis, Activity Assay, Expressing, Immune Cell, Two Tailed Test

Journal: Cell Reports Medicine

Article Title: STAT3 interference-driven nanomodulators reverse lipid metabolism-associated chemoresistance and potentiate metalloimmunotherapy in breast cancer

doi: 10.1016/j.xcrm.2026.102844

Figure Lengend Snippet: In vivo anti-tumor efficacy and immune evaluation (A) Schematic illustration of the in vivo treatment procedure. (B) Average tumor growth curves of each group. (C) H&E and Ki-67 staining of tumor sections (scale bar: H&E, 200 μm; Ki-67, 100 μm). (D) Immunofluorescence staining of NLRP3, C-Cas-1, and GSDMD-N in tumor sections (scale bar: 100 μm). (E) Schematic illustration of the immune evaluation procedure. (F–M) Flow cytometry analysis of CD80 + CD86 + DCs in CD11c + cells (F), CD8 + CD3 + T cells in CD45 + cells (G), CD4 + CD3 + T cells in CD45 + cells (H), IFN-γ + CD8 + T cells in CD3 + CD45 + cells (I), CD49b + NK cells in CD3 − CD45 + cells (J), the ratio of M1 to M2 macrophages (K), Foxp3 + CD4 + Tregs in CD3 + CD45 + cells (L), and Gr-1 + CD11b + MDSCs in CD45 + cells (M). (N) ELISA assay for the detection of the cytokines TNF-α, IL-1β, IFN-γ, and IL-12p70 within the tumor. (O) Schematic illustration of the treatment and evaluation procedure in combination with VX-765. (P) Average tumor growth curves of each group. (Q–V) Flow cytometry analysis of DCs (Q), CD8 + T cells (R), CD4 + T cells (S), NK cells (T), MDSCs (U), and Arg-1 + MDSCs (V). (W) Schematic illustration of the treatment procedure in combination with αLy6G/Ly6C (Gr-1). (X) Average tumor growth curves of each group. (Y) Immunofluorescence staining of CD8 and CD4 in tumor sections (scale bar: 100 μm). The data were presented as mean ± SD from n = 5. Statistical significance was calculated by two-way ANOVA comparison test in (B) by day 10 and in (P) and (X), one-way ANOVA with Dunnett’s comparison test in (F)–(M), and with Tukey’s comparison test in (Q)–(V).

Article Snippet: Belnacasan (VX-765) , MCE , Cat# HY-13205.

Techniques: In Vivo, Staining, Immunofluorescence, Flow Cytometry, Enzyme-linked Immunosorbent Assay, Comparison